Michael Farris
Overview
Explore the profile of Michael Farris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
260
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Glynn S, Shenker R, Razavian N, Patel Z, Steber C, Lanier C, et al.
Cureus
. 2025 Feb;
17(1):e76974.
PMID: 39912007
Purpose Small cell carcinoma of the lung (SCLC) often presents with brain metastases, with most patients developing them within a few years of diagnosis. Prophylactic cranial irradiation (PCI) is commonly...
2.
Price S, Willis A, Hensley A, Hyson J, Sohl S, DAgostino Jr R, et al.
Clin Lung Cancer
. 2024 Nov;
26(1):e41-e54.
PMID: 39490244
Purpose: The number of early-stage lung cancer survivors (LCS) is increasing, yet few survivorship programs address their specific needs. We developed a workflow to transition early-stage LCS to dedicated lung...
3.
Smith M, Dixon C, Wang Y, Liu Y, DAgostino Jr R, Ruiz J, et al.
Cancer Res
. 2024 Sep;
84(23):4002-4016.
PMID: 39250241
Treatment of non-small cell lung cancer (NSCLC) has drastically changed in recent years owing to the robust anticancer effects of immune checkpoint inhibitors (ICI). However, only 20% of the patients...
4.
Smith M, Wang Y, Dixon C, DAgostino R, Liu Y, Ruiz J, et al.
Clin Lung Cancer
. 2024 Aug;
25(8):e379-e388.
PMID: 39095235
Objectives: Compared to low-grade irAEs, high-grade irAEs are more often dose-limiting and can alter the long-term treatment options for a patient. Predicting the incidence of high-grade irAEs would help with...
5.
Razavian N, Farris M
Int J Radiat Oncol Biol Phys
. 2024 Feb;
118(3):587-588.
PMID: 38340765
No abstract available.
6.
Liu Y, Smith M, Wang Y, DAgostino Jr R, Ruiz J, Lycan T, et al.
Cancers (Basel)
. 2023 May;
15(9).
PMID: 37174093
The brain is one of the most common metastatic sites among breast cancer patients, especially in those who have Her2-positive or triple-negative tumors. The brain microenvironment has been considered immune...
7.
Smith M, Wang Y, DAgostino Jr R, Liu Y, Ruiz J, Lycan T, et al.
NPJ Precis Oncol
. 2023 Mar;
7(1):34.
PMID: 36973365
Different types of therapy are currently being used to treat non-small cell lung cancer (NSCLC) depending on the stage of tumor and the presence of potentially druggable mutations. However, few...
8.
Steber C, Hughes R, McTyre E, Soike M, Farris M, Levine B, et al.
Cureus
. 2021 Feb;
13(1):e12574.
PMID: 33575139
Purpose To determine the efficacy and toxicity of two standard chemotherapy regimens used concurrent with radiation for the treatment of esophageal cancer: cisplatin/5-fluorouracil (5-FU) and carboplatin/paclitaxel. Materials and methods We...
9.
McLouth L, Nightingale C, Levine B, Burris J, McDougall J, Lycan Jr T, et al.
JCO Oncol Pract
. 2021 Feb;
17(8):e1110-e1119.
PMID: 33539182
Purpose: Immunotherapy or chemoimmunotherapy is now standard treatment for most patients with metastatic non-small-cell lung cancer (mNSCLC), yet patient supportive care needs (SCNs) on immunotherapy are not well defined. This...
10.
Ahmed T, Lycan T, Dothard A, Ehrlichman P, Ruiz J, Farris M, et al.
Clin Lung Cancer
. 2020 Feb;
21(4):e286-e293.
PMID: 32089478
Introduction: Immunotherapy has become a key treatment for patients with advanced non-small-cell lung cancer (NSCLC). While a survival advantage has been proven for patients who are medically fit, it is...